Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
February 9, 2017
RegMed Investors’ (RMi) closing bell analysis, today’s upside is a response to the sector’s last three out of four negative closes
February 3, 2017
RegMed Investors’ (RMi) closing bell analysis, what’s driving the upside?
February 2, 2017
RegMed Investors’ (RMi) closing bell analysis, call me what you want
February 1, 2017
RegMed Investors’ (RMi) closing bell analysis, looking for value ‘tells’ at the sector’s table in the market’s casino
January 31, 2017
RegMed Investors’ (RMi) closing bell analysis, alternating closes divides sentiment
January 30, 2017
RegMed Investors’ (RMi) closing bell analysis, sector equities fell as sentiment imploded, again
January 27, 2017
RegMed Investors’ (RMi) closing bell analysis, the sector opened up, flipped down and regained ground at session’s end
January 26, 2017
RegMed Investors’ (RMi) closing bell analysis, pricing sustainability’s brawl continues
January 25, 2017
RegMed Investors’ (RMi) closing bell analysis, up today …
January 24, 2017
RegMed Investors’ (RMi) closing bell analysis, as the day evolves, the sector made a come back
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.